Open AccessPitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays
Author(s) -
MohammadAli Jenabian,
Frédéric Talla,
Perrine Talla,
François-Xavier Mbopi-Kéou,
Charlotte Charpentier,
Coumba Touré Kane,
Laurent Bélec
Publication year - 2015
Publication title -
nigerian medical journal/nigerian medical journal
Language(s) - English
Resource type - Journals
eISSN - 2229-774X
pISSN - 0300-1652
DOI - 10.4103/0300-1652.171613
Subject(s) - genotyping , drug resistance , virology , genotype , human immunodeficiency virus (hiv) , viral load , antiretroviral drug , biology , hiv drug resistance , lentivirus , medicine , gene , antiretroviral therapy , genetics , viral disease
HIV-1 genotyping for antiretroviral drug resistance mutations (DRMs) were developed based basically on subtype B HIV-1 Group M, which represents only 10% of HIV strains worldwide. In sub-Saharan Africa, non-B subtypes HIV-1 largely predominate and HIV-1 genetic diversity could affect the performance of drug resistance genotyping assays. We compared prospectively the performance of the ViroSeq(®) and Trugene(®) genotyping assays to detect DRM in HIV-1-infected adult patients living in Douala, Cameroun.